pdufa.bio
HomeReadouts › June 2026

June 2026 clinical-trial readouts

Updated ยทnext FDA decision on the calendar
trial-readout estimates for June 2026, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
July 2026 →
14 readouts
WVE · Jun 2026 (est.)
WVE-210201: Duchenne Muscular Dystrophy
LEGN · Jun 2026 (est.)
LCAR-B38M CAR-T Cell: B-Cell Non-Hodgkin Lymphoma-Recurrent
JAZZ · Jun 2026 (est.)
Zanidatamab: Gastroesophageal Adenocarcinoma
CLLS · Jun 2026 (est.)
UCART22: B-cell Acute Lymphoblastic Leukemia
CMPS · Jun 2026 (est.)
COMP360 psilocybin: Major Depressive Disorder
CELC · Jun 2026 (est.)
Gedatolisib: Breast Cancer
BMY · Jun 2026 (est.)
Nivolumab: Metastatic Renal Cell Carcinoma
OLMA · Jun 2026 (est.)
Palazestrant: Breast Cancer
TRVI · Jun 2026 (est.)
Nalbuphine ER Tablets: Idiopathic Pulmonary Fibrosis
ARDX · Jun 2026 (est.)
Tenapanor: Cystic Fibrosis
AGIO · Jun 2026 (est.)
Mitapivat: Anemia
ZBIO · Jun 2026 (est.)
Orelabrutinib: Warm Autoimmune Hemolytic Anemia
TLX · Jun 2026 (est.)
177Lu-TLX591: Clear Cell Renal Cell Carcinoma
PTCT · Jun 2026 (est.)
PTC923: Phenylketonuria
Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).